• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Fact Sheet - BioMolecular Products
Fact Sheet - BioMolecular Products

... Yesair, PhD., founder of BioMolecular Products, Inc. Dr. Yesair first described the physiologic arrangement between the principal products of fat digestion, lipids; specifically lysophosphatidylcholine (LPC), monoglyceride (MG), and fatty acid (FA). In the intestinal lumen, these lipids form a uniqu ...
Neurology Firm NuPathe Gets $15M For Lead Migraine Patch
Neurology Firm NuPathe Gets $15M For Lead Migraine Patch

Ibuprofen
Ibuprofen

... Changes resulting from the paediatric WS (DE/W/040/pdWS/001): SmPC sections 4.2 & 4.4, top of PIL and sections 2 & 3, and labelling ...
Monoclonal Anti-Factor X clone HX
Monoclonal Anti-Factor X clone HX

... Storage/Stability For continuous use, store at 2-8 C for up to one month. For extended storage freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples ...
Human Subjects Research Determination Form
Human Subjects Research Determination Form

... The activity is an experiment that involves a test article and one or more human subjects (as defined below) Note: For drugs, an experiment includes any use of a drug other than the use of a marketed (approved) drug in the course of medical practice. For medical devices, it is limited to activities ...
antiretroviral_Hamme..
antiretroviral_Hamme..

... The question of ‘When to Start Therapy?’ in an asymptomatic person has not been answered by randomized controlled clinical trials so the field has relied on a number of population based, cohort studies. The summary of these studies has shown consistently that delaying therapy until the CD4 count fal ...
(off-label) and without (unlicensed)
(off-label) and without (unlicensed)

... the drug from a medical, pharmaceutical and scientific viewpoint to ensure that it satisfies predefined criteria. Advice is sought from the Commission on Human Medicines (CHM), an independent advisory body, which in turn is assisted by specialist expert advisory groups. At a European level, the Comm ...
教案编写基本格式与要求
教案编写基本格式与要求

Drug Products, Labeling, and Packaging
Drug Products, Labeling, and Packaging

... The U.S. Orphan Drug Act of 1983 and similar programs in other countries have greatly expanded the number of therapies available to treat rare diseases through the use of financial and other incentives that encourage drug manufacturers to develop medications for limited patient populations. Despite ...
Saudi Drug Bulletin
Saudi Drug Bulletin

... following ICH Guidelines may be consulted: •• International Conference on Harmonisation. ICH Q5A (R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. --International Conference on Harmonisation. ICH Q5B: Analysis of the Expression Construction in ...
www.omics-ethics.org Revue de littérature: Mars
www.omics-ethics.org Revue de littérature: Mars

... Authors’   abstract:   Individual   variability   in   drug   efficacy   and   drug   safety   is   a   major   challenge  in  current  clinical  practice,  drug  development,  and  drug  regulation.  For  more  than   5  decades,  studies  o ...
Impending approval of a dangerous amphetamine drug
Impending approval of a dangerous amphetamine drug

... amfepramone. In 2000, the EMA withdrew the marketing authorisation of several appetite suppressants with a similar mechanism of action to that of amfepramone (clobenzorex, dexfenfluramine, fenfluramine, fenproporex, etc.), in order to protect public health (2). In 2009, sibutramine (Sibutral°), an a ...
Guidance regarding Psychoactive Substances
Guidance regarding Psychoactive Substances

drug product distribution requirements for pharmacy
drug product distribution requirements for pharmacy

Antidotes in food animal practice
Antidotes in food animal practice

... and enhance the excretion of a wide variety of toxicants. It is not soluble, and the particles are not absorbed through the intestinal mucosa. It is used as an adjunct treatment and is often combined with kaolin, another adsorptive agent. It may be used for treatment of pesticide and metal intoxicat ...
STATUS DECISION OF CONTROLLED AND NON
STATUS DECISION OF CONTROLLED AND NON

... and are not controlled under the CDSA. California Poppy extract is from a plant named Eschscholzia californica Cham.(papveraceae), the extracts of which have been reported to contain various compounds such as alkaloids, amino acids, and tannins. Studies on alcoholic extracts of E. californica Cham. ...
Collection of Real World Data in the Context of Rare
Collection of Real World Data in the Context of Rare

Ensemble Therapeutics Presents Oral Efficacy of First-in
Ensemble Therapeutics Presents Oral Efficacy of First-in

... “We have made dramatic progress since the first announcement of our small molecule IL-17 antagonist program earlier this year.” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics. “This data is compelling in showing excellent oral efficacy in vivo for several lead molecules, which puts us soli ...
Branded extended-release metformin, dru424
Branded extended-release metformin, dru424

... therapeutically equivalent to the branded product. Generic products are considered pharmaceutical equivalents with their branded counterparts, and are expected to have the same clinical effect and safety profile as the branded product when administered to patients under the conditions specified in t ...
However, the frequency of these four genotypes varies depending
However, the frequency of these four genotypes varies depending

... • 15-fold increase in percentage of patients on three or more psychiatric medications being seen at the Biological Psychiatry Branch of the National Institute of Mental Health from the early 1970s to the mid 1990s • Patients on psychiatric medications are at risk for DDIs and these DDIs are likely t ...
iCup Dx - TigerOfficer.com
iCup Dx - TigerOfficer.com

... »» Patented cup design; manufactured in our US facility »» Long shelf-life ...
shands - UF Health Professionals
shands - UF Health Professionals

Similarities and Differences Between Brand Name and
Similarities and Differences Between Brand Name and

What’s new in clinical Trials
What’s new in clinical Trials

... Why do we do clinical trials? • The American Public looks to its government for assurance that therapies developed to treat diseases are both SAFE and EFFECTIVE • The Food and Drug Administration (FDA) is charged with ensuring that safety and effectiveness are proven before a drug is put on pharmac ...
MedWatch - Boca Medical Products, Inc
MedWatch - Boca Medical Products, Inc

... other forms of treatment. If the drug is improperly used, it can cause severe side effects, including birth defects. Serious mental health problems have also been reported with isotretinoin use. The new webpage, http://www.fda.gov/buyonline/accutane, will appear in online search results for Accutane ...
< 1 ... 140 141 142 143 144 145 146 147 148 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report